Bio-Rad Laboratories, Inc. (BIO) Earnings Call Analysis
NYSE · Healthcare · Medical Devices
Next earnings call: 2026-08-04
(Q2 2026)
— full calendar
Earnings Reports
-
Bio-Rad (BIO) Q1 2026: Middle East Disruption Cuts $11M From Diagnostics, Margin Guidance Tightens
June 17, 2026
-
Bio-Rad (BIO) Q3 2025: Process Chromatography Delivers Double-Digit Growth, Offsetting U.S. Research Weakness
June 16, 2026
-
Bio-Rad (BIO) Q4 2025: Process Chromatography Set for Mid-Teens Decline, Reshaping Segment Mix
June 15, 2026
-
Bio-Rad (BIO) Q4 2025: Process Chromatography Slumps Mid-Teens, Margin Recovery Hinges on Operational Execution
June 15, 2026
-
Bio-Rad (BIO) Q2 2025: Process Chromatography Jumps 25%, Offsetting Academic Market Drag
July 31, 2025
-
BioRad (BIO) Q1 2025: Tariffs Cut 130bps From Margin as Life Science Softness Deepens
July 04, 2025
-
Bio-Rad (BIO) Q3 2024: Clinical Diagnostics Up 6%, Process Chrome Destocking Persists Into 2025
October 30, 2024
-
Bio-Rad (BIO) Q2 2024: Process Chromatography Declines 16%, Margin Expansion Offsets Life Science Drag
August 01, 2024
-
Bio-Rad (BIO) Q1 2024: Non-GAAP Operating Margin Drops to 9.7% as Process Chromatography Softens
May 07, 2024
-
Bio-Rad (BIO) Q4 2023: Life Science Revenue Down 19%, Diagnostics Steady as Recovery Hinges on H2
February 15, 2024